BRII BIOSCIENCES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.27 HKD | -2.31% |
|
-5.22% | -44.30% |
| May. 15 | Brii Bio's Hepatitis B Drugs Get Breakthrough Therapy Designation in China | MT |
| Mar. 25 | Transcript : Brii Biosciences Limited, 2023 Earnings Call, Mar 25, 2024 |
| Sales 2024 * | - | Sales 2025 * | 181M 24.95M 195M | Capitalization | 880M 121M 949M |
|---|---|---|---|---|---|
| Net income 2024 * | -528M -72.9M -570M | Net income 2025 * | -412M -56.88M -444M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 4.87 x |
| P/E ratio 2024 * |
-1.85
x | P/E ratio 2025 * |
-3.44
x | Employees | 128 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on Brii Biosciences Limited
More press releases
| 1 day | -2.31% | ||
| 1 week | -5.22% | ||
| Current month | +1.60% | ||
| 1 month | +27.00% | ||
| 3 months | -31.72% | ||
| 6 months | -60.19% | ||
| Current year | -44.30% |
1 week
1.24
1.50
1 month
0.961.50
Current year
0.852.39
1 year
0.854.20
3 years
0.8552.60
5 years
0.8552.60
10 years
0.8552.60
| Managers | Title | Age | Since |
|---|---|---|---|
Zhi Hong
CEO | Chief Executive Officer | 60 | 17-12-07 |
An Kang Li
DFI | Director of Finance/CFO | 47 | 20-08-31 |
David Margolis
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gregg Alton
BRD | Director/Board Member | 58 | 21-06-21 |
Tai Yin Yang
BRD | Director/Board Member | 70 | 22-08-31 |
Robert Nelsen
BRD | Director/Board Member | 60 | 18-06-21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.53% | 4 M€ | -27.92% | ||
| 0.00% | 4 M€ | -4.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 1.27 | -2.31% | 1 130 000 |
| 24-05-23 | 1.3 | -5.11% | 2,246,500 |
| 24-05-22 | 1.37 | +1.48% | 1,089,500 |
| 24-05-21 | 1.35 | -5.59% | 2,293,000 |
| 24-05-20 | 1.43 | +6.72% | 4,604,000 |
Delayed Quote Hong Kong S.E., May 24, 2024 at 04:08 am EDT
More quotes
Brii Biosciences Ltd is a biotechnology company based in China and the United States principally engaged in developing therapies for infectious diseases. The Companyâs products are applied in infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens. The Company is also developing therapies for COVID-19 and other diseases.
Calendar
2024-06-24
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.206
CNY
Average target price
5.536
CNY
Spread / Average Target
+359.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -44.30% | 121M | |
| +10.79% | 116B | |
| +11.65% | 106B | |
| -6.20% | 23.89B | |
| -3.44% | 21.58B | |
| -11.37% | 18.96B | |
| -13.41% | 16.33B | |
| -40.50% | 16.96B | |
| +6.64% | 14.14B | |
| +31.84% | 12.02B |
- Stock Market
- Equities
- 2137 Stock
